Core Insights - Tectonic Therapeutic, Inc. (NASDAQ:TECX) is recognized as one of the best micro-cap stocks to invest in according to analysts [1] - LifeSci Capital has reiterated a Buy rating on TECX with a price target of $88, indicating strong confidence in the stock's potential [2] Company Overview - Tectonic Therapeutic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCRs) [2][3] - The company has developed the GEODe technology platform to facilitate the discovery and development of GPCR-targeted biologic medicines [3] Product Pipeline - One of the lead product candidates is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, which is the GPCR target of the hormone relaxin [3] - Tectonic is also developing TX2100, aimed at treating hereditary hemorrhagic telangiectasia, and other GPCR modulators for treating fibrosis and related conditions [3]